NMNobuyuki Mizunuma

Nobuyuki Mizunuma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nobuyuki Mizunuma has a total of 198 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study.

    by Eiji Shinozaki, Megumi Ishiguro, Eiji Nakatani, Tatsuro Yamaguchi, Masato Nakamura, Yuji Miyamoto, Hitoshi Ojima, Yoshitaka Honma, Masahiro Gotoh, Toshiaki Ishikawa, et al.

    722 Background: For the patients with unresectable metastatic colorectal cancer (mCRC), response to the1st line chemotherapy has strong impact on their prognosis. Shrinkage of tumors may result in conversion to surgical resection and, concurrently, improved their survival. We conducted a multicenter phase II trial to investigate the efficacy and safety of panitumumab (Pmab) with chemotherapy as the 1st line treatment in Japanese patients with mCRC. Methods: Patients with no prior chemotherapy for unresectable, KRAS wild type mCRC, 20-80 years, and PS 0-1 were arbitrarily received either FOLFOX + Pmab or FOLFIRI + Pmab. Patients were evaluated every 8 weeks until progression. The primary endpoint was overall response rate (ORR), the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), R0 resection rate, and safety. Results: A total of 162 patients (140 with FOLFOX + Pmab and 22 with FOLFIRI + Pmab) were analyzed. Median follow-up was 28.2 months, median age at enrollment was 64.5 years, and 17.9% of the patients was recurrent disease. Number of target organ was 1 in 35.2%, 2 in 40.7%, and ≥ 3 in 24.1% of the subjects. Median administered cycle was 7, and median treatment duration was 16 weeks. ORR was 51.2% (95%CI: 43.3-59.2), and DCR was 82.1% (95%CI: 75.3-87.7). ≥ 30% tumor shrinkage (PR-in) was observed in 115 patients (71.0%). Median time to PR-in and maximum shrinkage was 10 and 16 weeks, respectively. Surgical resection was done in 66 patients (40.7%), of which R0 was in 43 patients; R0 resection rate was 26.5% (95%CI: 19.9-34.0). Median PFS and OS was 9.2 (95%CI: 7.2-11.4) and 33.8 months (95%CI: 29.4-43.1), respectively. ≥ Grade 3 adverse events with > 5% incidence were neutropenia (31.8%), stomatitis (10.5%), rash acneiform (9.9%), paronychia (9.3%), anorexia (8.6%), and diarrhea (6.2%). Conclusions: In our study, OS was favorable with high R0 resection rate, whereas ORR, DCR, PFS and toxicities were similar to those in previously reported studies. Because the maximum tumor shrinkage was observed around 16 weeks, optimal timing for considering conversion surgery might be 16 weeks from the start of treatment. Clinical trial information: UMIN000004991.


  • Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennaryN-glycan as a novel tumor marker for colorectal cancer.

    by Eiji Shinozaki, Kazuhiro Tanabe, Takashi Akiyoshi, Tomohiro Tsuchida, Yuko Miyazaki, Nozomi Kojima, Masahiro Igarashi, Masashi Ueno, Mitsukuni Suenaga, Nobuyuki Mizunuma, et al.

    595 Background: CEA and CA19-9 are measured widely in daily practice for colorectal cancer to monitor the condition of treatment, though its specificity and sensitivity is not satisfied enough. While, the innovation of mass spectrometry in this decade is dramatically. The revolutionized approach for the screening of glycomarkers provides a chance to discover more desirable tumor markers. We focused on glycan alterations of serum glycoproteins and tried to find new markers which are more specific and sensitive than the current markers. Methods: Sera of 80 CRC patients and 50 healthy volunteers were analyzed in this study. Glycopeptides were prepared from serum proteins by trypsin digestion, enriched by filtration and aleuria aurantia lectin(AAL), and then applied to liquid chromatography time-of flight mass spectrometry* (*LC-TOF-MS). Data was analyzed with our newly developed software, which calculates all of peak intensities and positions (m/z and elution time), aligns all peaks for all samples, and finally screens markers from a million of candidates. Results: Leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan (LRG-FTG) was discovered as a new CRC marker from over 100,000 candidate glycopeptide peaks. The level of LRG-FTG in CRC patients (1.25 ± 0.973 U/ml) was much higher than that of healthy parsons (0.496 ± 0.433 U/ml, p < 10-10). Its sensitivity and specificity exceeded those of CA19-9. CEA and LRG-FTG levels were moderately correlated (r = 0.61), however their relation was independent and complementary. Combination marker of LRG-FTG and CEA showed 84% of sensitivity, 90% of specificity and 0.91 of AUC (ROC analysis), and responded well to the efficacy of chemotherapy. Conclusions: Serum LRG-FTG was significantly elevated in CRC patients compared to healthy volunteers. The combination with CEA is expected to be an alternative diagnostic marker which distinguishes CRC from healthy persons and a sensitive monitoring marker for evaluation of efficacy during chemotherapy. Further validation study is warranted to evaluate serum LRG-FTG combination test compared with conventional tumor markers.

  • Self-reported adherence with TAS-102

    by Kazuo Sugita, Kazuyoshi Kawakami, Takashi Yokokawa, Takahito Sugisaki, Tomomi Takiguchi, Mitsukuni Suenaga, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Toshihiro Hama


  • Association between intratumoral HER2 heterogeneity (IHH) and trastuzumab (T-mab) efficacy in HER2 positive–gastric cancer (GC).

    by Takeru Wakatsuki, Noriko Yamamoto, Keisho Chin, Mariko Ogura, Eiji Shinozaki, Mitsukuni Suenaga, Masato Ozaka, Satoshi Matsusaka, Daisuke Takahari, Takashi Ichimura, et al.

    92 Background: ToGA study showed superiority of adding T-mab to standard chemotherapy and a positive correlation between HER2 expression levels and the T-mab efficacy. In gastric cancer IHH is frequently recognized but its clinical impact on T-mab efficacy is unclear. Methods: Patients who were treated with T-mab and had surgical specimens available for IHC test were retrospectively examined. When all tumor cells overexpressed HER2 protein by IHC, the tumor was defined as non-HER2-heterogeneous. The others were defined as HER2-heterogeneous. Progression-free survival (PFS) and overall survival (OS) were estimated using by Kaplan-Meier methods and compared by the log-rank test. The level of significance was set to p

  • A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study).

    by Mitsukuni Suenaga, Nobuyuki Mizunuma, Satoshi Matsusaka, Eiji Shinozaki, Masato Ozaka, Mariko Ogura, Keisho Chin, Toshiharu Yamaguchi

    758 Background: Re-introduction of oxaliplatin (L-OHP) for patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy regimens including L-OHP, irinotecan (CPT-11), and fluorouracil was thought to be effective approach. We performed a single arm, open-label phase II study (UMIN ID: 000004884), and the reported results of interim analysis were promising. Methods: Patients with prior chemotherapy including L-OHP and CPT-11 achieved tumor response or stable disease during prior L-OHP based therapy, and 6 months or over from confirmed progression disease during previous L-OHP based therapy was eligible for this study. Patients received FOLFOX regimens every two weeks. Primary endpoint was disease control rate (DCR) after 12 weeks of treatment start. Tumor response was evaluated by RECIST v1.1, and DCR was defined as complete response (CR), partial response (PR) or stable disease. This trial followed a Simon’s two-stage minimax design. Assuming the expected and threshold DCR after 12 weeks of treatment start would be 40% and 20%, 33 patients (18 in Step I and 15 in Step II) were required with a one sided α-level of 5% and a power of 80%. Results: Between February 2011 and August 2013, 33 patients were enrolled in this study. Characteristics of patients were as follows (n=33): median age of 62 years (35-77); male/female: 19/14; ECOG PS0: 84.8%; and colon/rectum: 14/19. All patients received mFOLFOX6 regimen. The DCR after 12 weeks of treatment start was 39.4% (95% CI: 21.8-57.0%), and the primary endpoint was met. The response Rate (CR or PR) was 6.1%. The median number of courses of chemotherapy was five, and the median total dose of L-OHP was 366.9 mg/m2. The median progression free survival was 98 days and the median overall survival was 300 days. The incidence of allergic reaction was 24.4% and peripheral neuropathy was 90.9%, graded as mild to moderate events. There were no other severe adverse events and treatment related deaths. Conclusions: Reintroduction of L-OHP was effective and could be a new salvage option for patients with mCRC refractory to previous L-OHP based therapy. Clinical trial information: 000004884.


  • Phenotypic differences among RAS mutational variations in colorectal cancer (CRC): Analysis of 1,001 patients in single institute.

    by Eiji Shinozaki, Yoshio Miki, Masashi Ueno, Masahiro Igarashi, Mitsukuni Suenaga, Keisho Chin, Masato Ozaka, Mariko Ogura, Daisuke Takahari, Takashi Ichimura, et al.

    649 Background: RAS mutation has been reported as a predictor of benefit from anti EGFR therapies in the recent sub-analysis of some large prospective trials, PRIME, FIRE-3 and so on. On the other hand, some in vitro experiments had identified the differences of capability of GTP bounding and colony formation according to KRAS mutational variations. It remains unknown whether there are phenotypic differences clinically among RAS mutational variations as potentially negative predictive factors for anti EGFR treatments. This study aimed to reveal the prevalence and the phenotypic differences of these variationsin a large cohort. Methods: Consecutive patients of 1,001 CRC from January 2012 to October 2013 were analyzed in this study. Multiplex genotyping of EGFR pathway was performed on archival samples using Luminex Assay (MABGEN and GENOSEARCH Mu-PACK, MBL) for KRAS including codons 61,146 and NRAS. We examined the correlation among mutation variations; KRAS G12D, G12V, G13D and other exon2, exon 3 and 4 and NRAS, and clinical phenotypic features. Statistical analysis was conducted by chi-square test. Results: The incidence of mutations; KRAS G12D, G12V, G13D, other exon2, exon 3 and 4, and NRAS were 16.2%, 10.0%, 6.4%, 7.0%, 4.6% and 3.5%, respectively. So called all RAS mutations were occupied in 47% in this cohort. There was no significant difference of prevalence among mutational variations according to clinical feature as follows; clinical stage, gender, age. In histopathology, moderately differentiated type of G12D was more frequent compared with other type of mutations. The respective proportion of KRAS exon 3 and 4, and NRAS mutationsfor left sided primary was relatively higher than those for right sided, although the frequency of other mutations were higher in right side. Conclusions: According to our analysis there were not so large phenotypic differences among these RAS mutational variations except histology and localization of primary. Futher follow up of this cohort will provide more information about treatment outcomes in near future.

  • Polymorphism of the chemokine CXCR4 to predict treatment benefit of first-line bevacizumab-based chemotherapy in patients with metastatic colorectal cancer.

    by Satoshi Matsusaka, Fotios Loupakis, Wu Zhang, Shu Cao, Dongyun Yang, Yan Ning, Stefan Stremitzer, Yu Sunakawa, Shinichi Yamauchi, Rita El-Khoueiry, et al.

    635 Background: The chemokine receptor CXCR4 and its ligand CXCL12 promote angiogenesis and the migration of tumor cells into the metastatic sites in many cancers. CXCR4 expression on tumor cells is upregulated by hypoxia and angiogenic factors, such as vascular endothelial growth factor. Therefore, we analyzed the association between CXCR4/CXCL12 polymorphisms and prognosis in metastatic colorectal cancer (mCRC) patients underwent bevacizumab-based chemotherapy. Methods: This study included 144 Japanese patients (pts) for evaluation set and 424 patients from two clinical trials (204 of TRIBE arm A and 220 of PROVETTA) for validation set, with mCRC treated with bevacizumab-based chemotherapy as first line. A total of 144 Japanese pts with (male/female; 81/63, median age 61 years, median follow-up 4.2 years) and 424 pts (male/female; 252/172, median age 62 years; median follow-up time; 2.8 years) were enrolled in a pharmacogenomics translational study. Genomic DNA was extracted from the pts’ blood or tissue. One CXCR4 single nucleotide polymorphisms (SNP) (rs2228014) and two CXCL12 SNPs (rs1801157, rs3740085) were analyzed by PCR-based direct sequencing. All candidate SNPs were analyzed for association with the clinical outcome. Results: In univariate analysis, CXCR4 rs2228014 showed a significant difference in PFS [(G/G 15.3 months, any A allele 13.7 months, HR (95% CI) 1.64 (1.01-2.68), p=0.036)]. After multivariate analysis, CXCR4 rs2228014 remained to be a significant for PFS [HR (95% CI) 1.67 (1.01-2.78), p =0.046]. However, this polymorphism was not associated with tumor response and survival. In the validation cohort, pts with GG genotype had significantly longer PFS compared to those with any A allele (10.5 vs 9.6 months, HR (95% CI) 1.40 (1.02-1.93), p =0.035). CXCL12 polymorphisms were not associated with the clinical outcome. Conclusions: This study shows for the first time that CXCR4 rs2228014 may serve as a predictive marker in patients with mCRC treated with bevacizumab-based chemotherapy.


  • The significance of EGFR pathway mutations for the efficacy of first line treatment with bevacizumab in metastatic colonrectal cancer.

    by Izuma Nakayama, Eiji Shinozaki, Takeru Wakatsuki, Yosuke Kumekawa, Mariko Ogura, Takashi Ichimura, Daisuke Takahari, Masato Ozaka, Mitsukuni Suenaga, Keisho Chin, et al.

    699 Background: After analysis of minor RAS mutations (KRAS exon3, 4/NRAS) in FIRE-3 or PRIME study, so called all RAS mutation would be being regarded as a biomarker for anti-EGFR antibodies. BRAF and PIK3CA mutation would be a candidate of biomarkers for anti EGFR targeted therapies. However it remains unknown whether EGFR pathway mutations affect the efficacy of bevacizumab in Stage.‡W CRC. Methods: Of the 1,001 consecutive patients of CRC in our institute between Nov 2006 and Dec 2013, we examined RAS, PIK3CA and BRAF mutational status, 141 patients received systemic chemotherapy for the first line treatment of Stage.‡W. Among them, 96 patients were administered chemotherapy with bevacizumab. Overall survival (OS), Time to Treatment Failure (TTF) and Objective Response Rate (ORR) were evaluated by mutational status. Results: Baseline characteristics were as follows (n=141): median age, 63; male/female, 80/61; ECOG PS 0-1/2, 135/4; chemotherapy with bevacizumab/chemotherapy with anti-EGFR antibodies/cytotoxic agent alone, 96/22/23;KRAS (codon 12,13) wild-type (WT)/RAS wild-type(WT), 89/80; PIK3CA mutation (exon 9/exon 20)/BRAF mutation, 11(5/6)/13. Median OS and TTF were 32.1 and 8.0 months respectively. In chemotherapy with bevacizumab, ORRs were 46.3% (all cases), 55.3% (KRAS WT), 54.5% (RAS WT) and 60.6% (all WT) respectively. ORR was gradually improved by focusing therapeutic target on all wild population. However, there were no significant differences in TTF and OS among them. PIK3CA mutation had a trend toward shorter TTF of bevacizumab (p=0.056). This trend was observed in PIK3CA mutation on exon 20 but not observed exon 9. BRAF mutation had significantly associated with poor OS not only for bevacizumab cases but also all therapies. Conclusions: In our study, profiling of EGFR pathway mutations may not contribute to enrich patients with benefit from chemotherapy with bevacizumab.

  • Patient's self-reported adherence to capecitabine on XELOX as adjuvant therapy for colorectal cancer.

    by Kazuyoshi Kawakami, Takashi Yokokawa, Kazuo Sugita, Akane Hagino, Kenichi Suzuki, Sayaka Oniyama, Satoshi Kohdo, Yohiaki Machida, Mitsukuni Suenaga, Nobuyuki Mizunuma, et al.

    690 Background: Capecitabine plus oxaliplatin (XELOX) has been established as adjuvant therapy for stage II/III colon cancer. Adherence to capecitabine is particularly important with XELOX to maintain appropriate curative effect. In this study, we monitored the adherence to capecitabine during adjuvant treatment with XELOX, and investigated the candidate factors that might decrease the adherence. Methods: The study included 139 consecutive patients who received XELOX treatment as adjuvant therapy for colorectal cancer between November 2011 and March 2014. Adherence to capecitabine was checked by pharmacists using a patient-reported treatment diary at a pharmaceutical outpatient clinic. Adherence rate was defined as the number of which a patient took capecitabine between d1 evening and d15 morning per 28 in each treatment cycle. The relative dose intensities and the deteriorating factors of adherence to capecitabine were retrospectively surveyed from electronic patient records. Results: 70 male and 69 female patients received adjuvant XELOX. Median adherence rate was 95.4% (n=139) in the first cycle of XELOX treatment, which gradually rose to 98.3% (n=121) in the eighth cycle. The median relative dose intensity of capecitabine was 76.7%. The main factors contributing to decreased adherence to capecitabine were diarrhea (34.7%) and nausea/vomiting (20.2%), peripheral neuropathy (10.7%). Conclusions: In this study, patient-reported adherence to capecitabine on XELOX treatment in clinical practice was highly maintained during all treatment cycles, and poor-adherence appeared to correlate with gastrointestinal events such as diarrhea, nausea, or vomiting. Our results suggest that assessment for compliance along with management of adverse events is needed to maintain treatment effect in clinical practice.

  • Endoscopic response evaluation of gastric primary lesion for chemotherapy compared to CT in advanced gastric cancer.

    by Keisho Chin, Yorimasa Yamamoto, Junko Fujisaki, Mariko Ogura, Eiji Shinozaki, Mitsukuni Suenaga, Nobuyuki Mizunuma

    50 Background: Significance of evaluation of gastric primary lesion with endoscopy remains unclear in chemotherapy (CTx) for advanced gastric cancer (AGC). Endoscopic evaluation is not necessary in RECIST. Methods: We compare the response of chemotherapy using RECIST by CT with or without upper GI endoscopy in AGC cases retrospectively. Among 175 cases of unresectable AGC treated by CTx in our institution between 2004 and 2008, we reviewed 141 evaluations in 74 cases which were examined by both endoscopy and CT within 2 weeks before and after CTx. Results: Patient backgrounds: Gender; M47/F27, Age; median 59(24-75), PS; 0or1=71/2=3, histological type; intestinal28/diffuse46, metastatic site; LN47/liver26/peritoneum29, CT per case; median number 4.5/ median interval 64.5days, endoscopy per case; median number 2/ median interval 91.3days. Response evaluation for gastric primary lesion between CT and endoscopy was compared in 141 examinations. Identical response 123(87.2%); both non-CR/non-PD 101/ both PD 22, not identical response 10(7.1%); endoscopy PD /CT non-CR/non-PD 10, not detected by CT; 8(5.7%). All of the cases of not identical response between CT and endoscopy were PD in endoscopy whereas non-CR/non-PD in CT. The overall response evaluation with or without endoscopy was concord in 133 evaluations (94.3%). Conclusions: It is almost appropriate that response evaluation of chemotherapy in AGC is mainly performed by CT without endoscopy to primary gastric lesion.